文章摘要
孙祥生,丁兆猛,王建荣.文拉法辛缓释片联合舒肝解郁胶囊治疗胃肠功能紊乱伴抑郁症 69例疗效观察[J].安徽医药,2019,23(12):2494-2497.
文拉法辛缓释片联合舒肝解郁胶囊治疗胃肠功能紊乱伴抑郁症 69例疗效观察
Efficacy and safety of venlafaxine combined with Shugan Jieyu capsule in the treatment of gastrointestinal disorders with depression:an analysis of 69 cases
  
DOI:10.3969/j.issn.1009?6469.2019.12.041
中文关键词: 胃肠疾病  消化不良  胃肠功能紊乱  抑郁症  文拉法辛  疏肝解郁药  不良反应
英文关键词: Gastrointestinal diseases  Dyspepsia  Gastrointestinal disorders  Depression  Venlafaxine  Depressed liver re? lieving drugs  Adverse reactions
基金项目:
作者单位
孙祥生 泰州市第四人民医院药剂科江苏泰州 225300 
丁兆猛 泰州市第四人民医院药剂科江苏泰州 225300 
王建荣 泰州市第四人民医院消化科江苏泰州 225300 
摘要点击次数: 2189
全文下载次数: 708
中文摘要:
      目的探讨文拉法辛缓释片联合舒肝解郁胶囊治疗胃肠功能紊乱伴抑郁症病人的疗效和安全性。方法选择 2016年 9月至 2017年 9月期间泰州市第四人民医院收治的胃肠功能紊乱伴抑郁症病人 136例,按随机数字表法分为对照组(67例)和观察组(69例)对照组病人接受文拉法辛口服治疗,每次 75 mg,每天 1次;观察组在此基础上联合舒肝解郁胶囊口服治疗,舒肝解郁胶囊 4粒/次,每,天 3次。两组病人均持续进行 6周的治疗。比较两组病人治疗后的疗效和安全性,并进行 6个月的随访调查。结果观察组病人胃肠功能紊乱治疗的总有效率 94.20%,高于对照组的 79.10%,差异有统计学意义(χ2=6.748,P< 0.05);治疗后,观察组各项症状积分均低于对照组;治疗后,观察组血清白细胞介素(IL)?6水平(75.2±9.7)pg/mL,抑郁评分(31.5±6.7)分,均低于对照组(81.5±11.3)pg/mL,(39.2±5.4)分,差异有统计学意义(t=3.492,7.366,均 P<0.05);对照组不良反应发生率 10.44%(7/67)与观察组的 5.79%(4/69)比较,差异无统学意义(χ2=1.173,P=0.278);经 6个月随访,观察组复发率 1.45%(1/69)低于对照组的 14.93%(10/67),差异有统计学意义(χ2=12.083,P=0.001)。结论文拉法辛联合舒肝解郁治疗胃肠功能紊乱伴抑郁症可有效提高临床疗效,促进抑郁症恢复,降低血清 IL?6水平,促进胃肠功能紊乱的改善,降低复发率,安全性高,值得推广。
英文摘要:
      Objective To investigate the efficacy and safety of venlafaxine combined with Shugan Jieyu capsule in the treatment of gastrointestinal disorders with depression.Methods A hundred and thirty?six patients with gastrointestinal disorders and depres? sion,treated in the Fourth People’s Hospital of Taizhou from September 2016 to September 2017.were selected and randomly as? signed into control group(67 cases)and observation group(69 cases).The patients in control group were treated with venlafaxine, 75 mg orally once a day,while the patients in the observation group were treated with additional Shugan Jieyu capsule,4 capsulesorally three times a day.All the patients were treated for 6 weeks.The efficacy and safety of the two groups after treatment were com?pared and patients were followed up for 6 months.Results The total effective rate of gastrointestinal disorders in the observation group was 94.20%,which was higher than that in the control group(79.10%)(χ2=6.748,P<0.05).After treatment,the scores of the symptoms in the observation group were lower than those of the control group;the serum IL?6 level and the depression score in the observation group were both lower than those in the control group[(75.2 ± 9.7)pg/mL vs.(81.5±11.3)pg/mL,(31.5 ± 6.7) points vs.(39.2±5.4)points],and the differences were statistically significant(t=3.492,7.366,both P<0.05).There was no significant difference in the incidence of adverse reaction between the control group(10.44%,7/67)and the observation group(5.79%,4/69)(χ2=1.173,P=0.278).After 6 months of follow?up,the recurrence rate in the observation group was 1.45%(1/69)which was low? er than that in the control group(14.93%,10/67),and the difference was statistically significant(χ2=12.083,P=0.0,01).Conclu? sion In the treatment of gastrointestinal disorders with depression,venlafaxine combined with Shugan Jieyu capsule can effective? ly improve the clinical efficacy,promote the recovery of depression,reduce serum IL?6 level,improve gastrointestinal dysfunction and reduce the recurrence rate,which is safe and worthy of promotion.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮